Q4 Earnings Estimate for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – HC Wainwright lowered their Q4 2026 EPS estimates for shares of OPKO Health in a research note issued on Monday, March 2nd. HC Wainwright analyst Y. Chen now expects that the biotechnology company will earn ($0.08) per share for the quarter, down from their prior estimate of ($0.07). The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

A number of other brokerages also recently issued reports on OPK. Wall Street Zen raised OPKO Health from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Barrington Research dropped their price objective on shares of OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. Finally, JPMorgan Chase & Co. began coverage on shares of OPKO Health in a research note on Thursday, November 20th. They set a “neutral” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $2.03.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.17 on Thursday. The business’s 50 day moving average price is $1.26 and its 200 day moving average price is $1.35. The company has a market cap of $888.11 million, a price-to-earnings ratio of -3.90 and a beta of 1.50. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.32 and a current ratio of 3.97. OPKO Health has a one year low of $1.11 and a one year high of $1.95.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. The business had revenue of $148.50 million for the quarter, compared to analysts’ expectations of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.During the same period in the previous year, the firm posted $0.01 EPS. The business’s revenue for the quarter was down 19.1% compared to the same quarter last year.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd lifted its holdings in shares of OPKO Health by 1,056.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 39,232 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 35,841 shares during the last quarter. Virtu Financial LLC purchased a new stake in OPKO Health in the fourth quarter valued at approximately $145,000. EP Wealth Advisors LLC acquired a new position in OPKO Health during the fourth quarter worth $37,000. XTX Topco Ltd purchased a new position in shares of OPKO Health during the fourth quarter worth $432,000. Finally, Zacks Investment Management purchased a new position in shares of OPKO Health during the fourth quarter worth $27,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.